2004 studies found for:    myeloma
Show Display Options
Rank Status Study
1 Active, not recruiting Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: aMILs;   Biological: Allogeneic Myeloma Vaccine
2 Recruiting Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
Conditions: Multiple Myeloma;   Leukemia;   Lymphoid;   Lymphoma;   Non-Hodgkin
Interventions: Other: Chronic Lymphocytic Leukemia (CLL);   Other: Multiple Myeloma (MM);   Other: Non-Hodgkin's lymphoma (NHL)
3 Active, not recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
4 Completed
Has Results
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine;   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine Sulfate;   Drug: Methotrexate;   Biological: GMCSF (granulocyte macrophage colony stimulating factor);   Biological: GCSF (granulocyte colony stimulating factor)
5 Recruiting Role of Osteocytes in Myeloma Bone Disease
Condition: Multiple Myeloma
6 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
7 Completed Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Conditions: Cancer;   Myeloma;   Multiple Myeloma
Intervention: Drug: Bortezomib
8 Unknown  Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Condition: Multiple Myeloma
9 Active, not recruiting A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: CB-5083;   Drug: Dexamethasone
10 Terminated
Has Results
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
11 Active, not recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
12 Completed Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Conditions: Graft vs Host Disease;   Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine-KLH;   Drug: GM-CSF
13 Active, not recruiting Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine;   Biological: Prevnar-13
14 Unknown  Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
15 Unknown  Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib + Dexamethasone
16 Completed Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: CC-5013
17 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
18 Completed High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: High-Dose Sequential Chemotherapy followed by ASCT
19 Completed
Has Results
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: MAGE-A3;   Biological: MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
20 Completed A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
Conditions: Malignant Solid Tumor;   Lymphomas;   Multiple Myeloma
Interventions: Biological: AV-299;   Biological: AV-299 + erlotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years